Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup BioPharma DiveCohen says he looked at around two dozen companies since Acorda wound down.PipelineNeuroscienceRead full story pharminent March 24, 2026 (Last updated: March 24, 2026) BioPharma Dive Cohen says he looked at around two dozen companies since Acorda wound down. PipelineNeuroscience Read full story Post navigation Previous: Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study resultsNext: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers Related Stories Pipeline Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models pharminent September 2, 2026 Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026